John Andrews is a senior research executive with more than 25 years of academic and industrial research experience in the field of central nervous system drug discovery. Dr. Andrews completed a PhD in Neuroendocrinology and post-doctoral research at Emory University, followed by a career in industry, initially in major pharma companies such as Schering AG, Organon and culminating in a role as Vice President, CNS Discovery at Janssen/J&J. Dr. Andrews then became a founding member in Descartes and a co-founder of NeurAxon Inc. These positions have all involved developing innovative research projects in the CNS, particularly in the areas of psychiatry, pain and neurodegenerative disorders; several projects have progressed from the bench to registration and sales. NeurAxon is developing selective NOS inhibitors for use in pain and other CNS disorders, the first compound developed inhouse is in Phase II clinical trials with others projected to follow shortly.